Hanwha Corp
https://www.hanwhacorp.co.kr/eng/index.jsp
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Hanwha Corp
Interview: Fledgling ABL Bio And Its Global Ambitions In Bispecific Antibodies
South Korea’s ABL Bio is tackling cancer and neurodegenerative diseases with its broad bispecific antibody pipeline and CEO Sang Hoon Lee outlines the firm’s multi-collaboration and licensing strategy.
Korea Mulls New Biosimilar Guidelines As Pipeline Surges
As more biosimilar products are set to be released in South Korea, with a hefty number of ongoing late-stage clinical trials, the country is seeking to introduce a new separate guideline for insulin biosimilars. While South Korea has introduced biosimilar guidelines relatively earlier than some others, a local institute suggests these still need to be improved, pointing to a lack of clarity and implementation issues.
Korean Green Light For Samsung Bioepis’s Biosimilar Etanercept
Within just three and a half years since its establishment, Samsung Bioepis has received its first regulatory approval for a biosimilar, meaning the Samsung Group affiliate is now set to release its version of Amgen’s Enbrel (etanercept) in South Korea late this year or early next. It will be the fourth locally developed biosimilar to hit the domestic market and is expected to be priced at about a 30% discount.
Biologics World Korea: Counting On A Paradigm Shift In Biologics Market
Biopharmaceutical experts from around the world gathered in Seoul at the recent Biologics World Korea 2015, at which a group of panelists discussed the strategic direction of the biologics industry in Asia and a paradigm shift in the global biologics market.
Company Information
- Industry
- Contract Manufacturing Organization
- Other Names / Subsidiaries
-
- DreamPharma Corp.
- Hanwha Chemical Corporation
- Hanwha Europe GmbH
- Hanwha Group
- Hanwha Living and Creative Corporation
- Yeochun NCC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice